KAMADA LTD KMDA

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $180.5M$161.0M$142.5M$129.3M$103.6M$133.2M$127.2M$114.5M$102.8M$77.5M
SG&A ————$12.6M$10.1M$9.2M$8.5M——
Operating income $26.2M$20.1M$10.1M$4.5M-$696.0K$19.2M$22.8M$19.3M$7.4M-$5.5M
Net income $20.2M$14.5M$8.3M-$2.3M-$2.2M$17.1M$22.3M$22.3M$6.9M-$6.7M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Short-term investments —————$39.1M$31.2M———
Total assets $378.7M$372.3M$354.9M$322.4M$318.7M$210.7M$173.8M$138.1M$122.1M$99.7M
Total current liabilities —————$222.0K————
Total equity $269.1M$259.5M$244.0M$176.0M$176.8M$178.6M$135.3M$112.4M$89.5M$66.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-025934.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -50M 0 50M 100M 150M 200M Revenue, FY2016: 77.5M Net income, FY2016: -6.7M Revenue, FY2017: 102.8M Net income, FY2017: 6.9M Revenue, FY2018: 114.5M Net income, FY2018: 22.3M Revenue, FY2019: 127.2M Net income, FY2019: 22.3M Revenue, FY2020: 133.2M Net income, FY2020: 17.1M Revenue, FY2021: 103.6M Net income, FY2021: -2.2M Revenue, FY2022: 129.3M Net income, FY2022: -2.3M Revenue, FY2023: 142.5M Net income, FY2023: 8.3M Revenue, FY2024: 161M Net income, FY2024: 14.5M Revenue, FY2025: 180.5M Net income, FY2025: 20.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $77.5M $102.8M $114.5M $127.2M $133.2M $103.6M $129.3M $142.5M $161.0M $180.5M
Gross profit — — — — — — — — — —
Net income -$6.7M $6.9M $22.3M $22.3M $17.1M -$2.2M -$2.3M $8.3M $14.5M $20.2M

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%